摘要
目的:探讨依托泊苷联合沙利度胺治疗对非小细胞肺癌患者的有效性及血清VEGF水平的影响。方法:选取2017年6月-2018年6月本院收治的106例非小细胞肺癌患者为研究对象,依据随机数字表法分为研究组和对照组,各53例。对照组应用依托泊苷治疗,研究组应用依托泊苷联合沙利度胺治疗。观察比较两组患者的疗效、副作用、血清指标、生活质量及2年生存率情况。结果:研究组的有效率高于对照组,副作用发生率低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组TNF-α、VEGF及bFGF血清指标均低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组PF、RP、BP、GH、VT、SF及RE评分均高于对照组,差异均有统计学意义(P<0.05)。研究组1、2年生存率均高于对照组,差异均有统计学意义(P<0.05)。结论:依托泊苷与沙利度胺联合治疗非小细胞肺癌患者效果显著,不仅可以降低血清中的各项指标,还可以提高其生活质量,降低副作用发生的风险,延缓病情进展,安全性高,有利于进一步提高患者2年生存率,对改善患者预后效果具有重要意义,是一种安全、有效的治疗方式,值得临床大力推广。
Objective:To investigate the efficacy of Etoposide combined with Thalidomide in the treatment of non-small cell lung cancer(NSCLC)and the effect of serum VEGF level.Method:A total of 106 patients with NSCLC admitted to our hospital from June 2017 to June 2018 were selected as study subjects.The patients were divided into study group and control group by random number table method,53 cases in each group.The control group was treated with Etoposide,while the study group was treated with Etoposide combined with Thalidomide.The efficacy,side effects,serum indicators,quality of life and 2-year survival rate of the two groups were observed and compared.Result:The effective rate of the study group was higher than that of the control group,and the side effects were lower than that of the control group,with statistically significant differences(P<0.05).After treatment,serum indexes of TNF-α,VEGF and bFGF in the study group were all lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,PF,RP,BP,GH,VT,SF and RE scores of the study group were all higher than those of the control group,with statistically significant differences(P<0.05).The 1-year and 2-year survival rates in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Etoposide combined with Thalidomide in the treatment of patients with NSCLC has a significant effect,it can not only reduce the indicators in serum,but also improve the quality of life,reduce the risk of side effects such as vomiting and anorexia,delay the progress of the disease,with high safety,which is conducive to further improve the 2-year survival rate of patients,it is of great significance to improve the prognosis of patients,and it is a safe and effective treatment method,which is worthy of clinical promotion.
作者
聂树志
NIE Shuzhi(Liaoyang Second People’s Hospital,Liaoyang 111000,China)
出处
《中国医学创新》
CAS
2021年第2期40-44,共5页
Medical Innovation of China
